NCT06495593View on ClinicalTrials.gov

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

PHASE4RecruitingINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Ocrelizumab

Standard ocrelizumab dosing

Trial Locations (1)

94158

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT06495593 - Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis | Biotech Hunter | Biotech Hunter